Skip to main content
. 2022 Apr 11;269(7):3937–3958. doi: 10.1007/s00415-022-11063-5

Table 3.

Non-randomised, controlled clinical trial. OCEBM level of evidence 2b

 Authors Year published Country Phase No. of Patients Age MS Duration (y) Type of MS EDSS (baseline) Follow-up (y) EDSS (final) PFS (y) Death due to aHSCT
Intermediate-intensity, myeloablative
 Mariottini et al. 2019 Italy II 11 (52 total) 35 10.5 RRMS 3.25 3 44.4% improved 0